 |
|
|
| |
Pharmacokinetic Analyses of Ledipasvir/Sofosbuvir in HCV-Infected Subjects
With Advanced Liver Disease and/or Following Liver Transplantation
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Kimberly L. Garrison, Polina German, Sarah Arterburn, Shampa De-Oertel, Diana M. Brainard, John Ling, Feng Jin, Anita Mathias
Gilead Sciences, Inc., Foster City, California, USA
References
1. Berry PA, Thomson SJ. Acute Med 2013;12:232-8;
2. Fink SA, Jacobson IM. Nat Rev Gastroenterol Hepatol 2011;8:285-95;
3. Adam R, et al. Liver Transpl 2003;9:1231-43;
4. Kim WR, et al. Am J Transplant 2014;14:69-96;
5. Gane E, et al. AASLD 2015, abstr 1049;
6.Manns M, et al. J Hepatol 2015;62(suppl 2):187-8;
7. Mathias A, et al. AASLD 2012, abstr 1869;
8. Charlton M, et al. Gastroenterology 2015;149:649-59;
9. Manns M, et al. Lancet Infect Dis 2016 Feb 18 [Epub ahead of print];
10. Kirby B, et al. 15th International Workshop
on Clinical Pharmacology of HIV & Hepatitis Therapy 2014, abstr P_33;
11. Lawitz E, et al. EASL 2012, abstr 1130;
12. Charlton M, et al. Gastroenterology 2015;148:108-17;
13. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc., 2016;
14. Harvoni [SmPC]. Foster City, CA: Gilead Sciences, Inc., 2016.
|
| |
|
|
|
|
|
